PRG-1801
PRG1801E13
Phase 1 small_molecule active
Quick answer
PRG-1801 for Immune Thrombocytopenia is a Phase 1 program (small_molecule) at Hospital Authority, Hong Kong with 1 ClinicalTrials.gov record(s).
Program details
- Company
- Hospital Authority, Hong Kong
- Indication
- Immune Thrombocytopenia
- Phase
- Phase 1
- Modality
- small_molecule
- Status
- active